A new clinical trial is exploring the potential of IPH4502, an antibody-drug conjugate (ADC) targeting Nectin-4, in patients with advanced solid tumors.
IPH4502 delivers a potent topoisomerase I inhibitor directly to Nectin-4-expressing cancer cells, sparing healthy tissue. The Phase 1 study is evaluating its safety, tolerability, and preliminary efficacy, with a focus on determining the recommended Phase 2 dose. This trial builds on preclinical research showing promising antitumor activity across multiple cancers, including breast, lung, ovarian, and prostate cancer.
Update on Prostate Cancer Vaccines from Previous Posts done 1 year ago
